FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063738525> ?p ?o ?g. }

• W2063738525 endingPage "345" @default.
• W2063738525 startingPage "335" @default.
• W2063738525 abstract "Vigabatrin, an inhibitor of GABA breakdown by GABA transaminase and of GABA transporter isoform 1 (GAT1), and tiagabine, a highly specific inhibitor of GAT1, have successfully been applied in the treatment of epilepsy. We investigated the effects of individual and combined application of these drugs on GAT1 expressed in Xenopus oocytes, and examined the effects on epileptiform discharges in the CA3 area of brain slices of genetically epileptic El and control ddY mice, and on the occurrence of seizures in El mice. Simultaneous application of vigabatrin and tiagabine inhibited epileptiform discharges induced by high-K+ solution in the brain slices in an antagonistic fashion. The degree of inhibition by tiagabine after pre-treatment with vigabatrin was additive in ddY mice and synergistic in El mice. In Mg2+-free solution, co-treatment by the two drugs produced additive inhibition in slices from both mouse strains, but pre-treatment with vigabatrin produced synergistic inhibition in slices only from ddY mice. In the slices from El mice, a combination of drugs resulted in additive effects in both co- and pre-treatment by the drugs. Although these drugs are also effective in vivo at suppressing seizure occurrence in El mice, the combined application does not show synergistic effects, but rather is antagonistic under the experimental conditions in this particular variant of epilepsy. The synergistic inhibition of epileptiform discharges in brain slices may, in part, have originated from the complex interaction with GAT1. In experiments on the GAT1 expressed in oocytes it could be demonstrated that synergistic inhibition occurs only at low concentration (0.1 nM) of vigabatrin. This illustrates that the oocytes may form a powerful test system for drug screening and investigation of complex drug interactions. These results present a novel interpretation of synergistic inhibition of certain epileptic discharges using vigabatrin and another drug, and that for successful synergistic treatment of epilepsies carefully designed timed dosage regimens are essential." @default.
• W2063738525 created "2016-06-24" @default.
• W2063738525 creator A5025725057 @default.
• W2063738525 creator A5038381848 @default.
• W2063738525 creator A5041306034 @default.
• W2063738525 date "2005-01-01" @default.
• W2063738525 modified "2023-10-14" @default.
• W2063738525 title "Antiepileptic action induced by a combination of vigabatrin and tiagabine" @default.
• W2063738525 cites W1533853049 @default.
• W2063738525 cites W1880195515 @default.
• W2063738525 cites W1993673975 @default.
• W2063738525 cites W1994310082 @default.
• W2063738525 cites W2010687489 @default.
• W2063738525 cites W2010819337 @default.
• W2063738525 cites W2014037505 @default.
• W2063738525 cites W2015176438 @default.
• W2063738525 cites W2026172017 @default.
• W2063738525 cites W2030254120 @default.
• W2063738525 cites W2035271231 @default.
• W2063738525 cites W2041882230 @default.
• W2063738525 cites W2057552859 @default.
• W2063738525 cites W2058107876 @default.
• W2063738525 cites W2066297515 @default.
• W2063738525 cites W2066748804 @default.
• W2063738525 cites W2071098232 @default.
• W2063738525 cites W2074788730 @default.
• W2063738525 cites W2075157564 @default.
• W2063738525 cites W2086124772 @default.
• W2063738525 cites W2093211059 @default.
• W2063738525 cites W2095522927 @default.
• W2063738525 cites W2124813072 @default.
• W2063738525 cites W2129494871 @default.
• W2063738525 cites W2133743587 @default.
• W2063738525 cites W2139556822 @default.
• W2063738525 cites W2145869886 @default.
• W2063738525 cites W2158303290 @default.
• W2063738525 cites W2170550330 @default.
• W2063738525 cites W2334628654 @default.
• W2063738525 cites W2336462557 @default.
• W2063738525 cites W2408615049 @default.
• W2063738525 cites W2425728667 @default.
• W2063738525 cites W252392925 @default.
• W2063738525 cites W3179996438 @default.
• W2063738525 doi "https://doi.org/10.1016/j.neuroscience.2004.12.044" @default.
• W2063738525 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15802187" @default.
• W2063738525 hasPublicationYear "2005" @default.
• W2063738525 type Work @default.
• W2063738525 sameAs 2063738525 @default.
• W2063738525 citedByCount "11" @default.
• W2063738525 countsByYear W20637385252012 @default.
• W2063738525 countsByYear W20637385252013 @default.
• W2063738525 countsByYear W20637385252014 @default.
• W2063738525 countsByYear W20637385252017 @default.
• W2063738525 countsByYear W20637385252021 @default.
• W2063738525 crossrefType "journal-article" @default.
• W2063738525 hasAuthorship W2063738525A5025725057 @default.
• W2063738525 hasAuthorship W2063738525A5038381848 @default.
• W2063738525 hasAuthorship W2063738525A5041306034 @default.
• W2063738525 hasConcept C104317684 @default.
• W2063738525 hasConcept C149011108 @default.
• W2063738525 hasConcept C150903083 @default.
• W2063738525 hasConcept C169760540 @default.
• W2063738525 hasConcept C181199279 @default.
• W2063738525 hasConcept C185592680 @default.
• W2063738525 hasConcept C207001950 @default.
• W2063738525 hasConcept C2775858608 @default.
• W2063738525 hasConcept C2776749334 @default.
• W2063738525 hasConcept C2777421860 @default.
• W2063738525 hasConcept C2778186239 @default.
• W2063738525 hasConcept C2779046065 @default.
• W2063738525 hasConcept C2780837902 @default.
• W2063738525 hasConcept C55493867 @default.
• W2063738525 hasConcept C86803240 @default.
• W2063738525 hasConcept C9497952 @default.
• W2063738525 hasConcept C98274493 @default.
• W2063738525 hasConceptScore W2063738525C104317684 @default.
• W2063738525 hasConceptScore W2063738525C149011108 @default.
• W2063738525 hasConceptScore W2063738525C150903083 @default.
• W2063738525 hasConceptScore W2063738525C169760540 @default.
• W2063738525 hasConceptScore W2063738525C181199279 @default.
• W2063738525 hasConceptScore W2063738525C185592680 @default.
• W2063738525 hasConceptScore W2063738525C207001950 @default.
• W2063738525 hasConceptScore W2063738525C2775858608 @default.
• W2063738525 hasConceptScore W2063738525C2776749334 @default.
• W2063738525 hasConceptScore W2063738525C2777421860 @default.
• W2063738525 hasConceptScore W2063738525C2778186239 @default.
• W2063738525 hasConceptScore W2063738525C2779046065 @default.
• W2063738525 hasConceptScore W2063738525C2780837902 @default.
• W2063738525 hasConceptScore W2063738525C55493867 @default.
• W2063738525 hasConceptScore W2063738525C86803240 @default.
• W2063738525 hasConceptScore W2063738525C9497952 @default.
• W2063738525 hasConceptScore W2063738525C98274493 @default.
• W2063738525 hasIssue "2" @default.
• W2063738525 hasLocation W20637385251 @default.
• W2063738525 hasLocation W20637385252 @default.
• W2063738525 hasOpenAccess W2063738525 @default.
• W2063738525 hasPrimaryLocation W20637385251 @default.
• W2063738525 hasRelatedWork W1514118911 @default.

• next